Interventions of Interest: Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; sotatercept would achieve common thresholds for cost-effectiveness if priced between $17,900 to $35,400 per year. Final Documents ICER’s Chief Medical Officer, David Rind, MD: “Pulmonary arterial hypertension is a progressive disease that can lead to debilitating […]
Interventions of Interest: Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 – $5,700 per year. At the January 20 virtual meeting, ICER’s independent appraisal committee will review the evidence, […]
Interventions of Interest: Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently adequate to demonstrate a net health benefit of mavacamten added to background therapy. Using estimates from modeling of short-term benefits, mavacamten does show an overall benefit but would have to be priced below $15,000 per […]
In June 2018, ICER announced its intention to assess the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. However, in October 2018, when the Food and Drug Administration declined to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease, ICER announced it would no longer proceed with its value assessment. […]
Intervention of interest: Cardiac nuclear imaging ICER completed a Technology Assessment of cardiac nuclear imaging for the public meeting of the Washington State Health Technology Assessment Program’s Clinical Committee. Date of review: September 2013 Final Documents Below you will find the final documents from the assessment review process:
Interventions of interest: Antiarrhythmic drug therapy to return the heart to sinus rhythm Radiofrequency catheter ablation to terminate AF and prevent further episodes Minimally-invasive surgical techniques to terminate AF and prevent further episodes Aspirin, warfarin, and dabigatran for anticoagulation to prevent strokes The WATCHMAN left atrial appendage occlusive device to prevent strokes Atrial fibrillation (AF) […]
Interventions of interest: Coronary computed tomographic angiography Coronary computed tomographic angiography (CCTA) is a minimally invasive radiological technique used to provide images of the heart and surrounding vessels. CCTA has been suggested as an alternative or useful complementary approach to other non-invasive methods of diagnosing coronary artery disease (CAD). Date of review: January 2009 For […]
Interventions of interest: inclisiran (Leqvio®, Novartis) bempedoic acid (Nexletol®, Esperion Therapeutics) bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics) An independent appraisal committee voted that the evidence is not adequate to demonstrate a net health benefit of bempedoic acid over usual care for the entire population of eligible patients, but is adequate when focused on patients unable to […]
Interventions of Interest: alirocumab (Praluent®, Regeneron/Sanofi) evolocumab (Repatha®, Amgen) Cardiovascular disease (CVD) is the most common cause of death in the United States and approximately one third of American adults have CVD. Low density lipoprotein cholesterol (LDL) is a major modifiable risk factor for myocardial infarction, stroke, and death from cardiovascular disease. The use of […]
Interventions of interest: Antiarrhythmic drugs (amiodarone, dronedarone) Catheter ablation Surgical ablation Atrial fibrillation (AF) is the most common cardiac arrhythmia in the US population. AF occurs when rapid, disorganized electrical signals cause the atria (the two upper chambers of the heart) to “fibrillate”, or contract quickly and irregularly. This in turn causes some blood to […]